abacavir/lamivudine viatris 600 mg/300 mg apvalkotās tabletes
viatris limited, ireland - abacavirum, lamivudinum - apvalkotā tablete - 600 mg/300 mg
dutasteride/tamsulosin viatris 0,5 mg/0,4 mg cietās kapsulas
viatris limited, ireland - dutasteridum, tamsulosini hydrochloridum - kapsula, cietā - 0,5 mg/0,4 mg
dasatinib viatris 50 mg apvalkotās tabletes
viatris limited, ireland - dasatinibs - apvalkotā tablete - 50 mg
ticagrelor viatris 90 mg apvalkotās tabletes
viatris limited, ireland - ticagrelorum - apvalkotā tablete - 90 mg
apixaban viatris 2,5 mg apvalkotās tabletes
viatris limited, ireland - apiksabāns - apvalkotā tablete - 2,5 mg
apixaban viatris 5 mg apvalkotās tabletes
viatris limited, ireland - apiksabāns - apvalkotā tablete - 5 mg
pazopanib viatris 200 mg apvalkotās tabletes
viatris limited, ireland - pazopanibs - apvalkotā tablete - 200 mg
pazopanib viatris 400 mg apvalkotās tabletes
viatris limited, ireland - pazopanibs - apvalkotā tablete - 400 mg
faslodex
astrazeneca ab - fulvestrant - krūts audzējs - endokrīnās terapijas, anti-estrogēnu - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. , pirms vai perimenopausal sievietes, kombinējot ārstēšanu ar palbociclib būtu jāapvieno ar luteinizējošais hormona atbrīvojošo hormonu (lhrh) agonistu.
nemdatine
actavis group ptc ehf. - memantine - alcheimera slimība - psychoanaleptics, , citas anti-demenci zāles - pacientiem ar vidēji smagu vai smagu alcheimera slimību ārstēšana.